Present and Future Anticoagulants

Advances in Anesthesia

Volumn 24, Issue , 2006, Pages 29-66

  Stone, Marc E ^a   Shore Lesserson, Linda ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750613308     PISSN: 07376146     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.aan.2006.06.002     Document Type: Review

References (217)

1. Deitcher S.R. Antiplatelet, anticoagulant and fibrinolytic therapy. In: Kasper D.L., Braunwald E., Fauci A., et al. (Eds). Harrison's principles of internal medicine. 16th edition (2005), McGraw-Hill, Inc, New York
2. Cines D.B., Polack E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91 (1998) 3627-3661
3. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 17 Suppl 1 (2003) S1-S5
4. Badimon L., Meyer B.J., and Badimon J.J. Thrombin in arterial thrombosis. Haemostasis 24 (1994) 69-80
5. Thompson E.A., and Salem H.H. Inhibition by human thrombomodulin of factor Xa-mediated cleavage of prothrombin. J Clin Invest 78 1 (1986) 13-17
6. Esmon C.T., and Fukudome K. Cellular regulation of the protein C pathway. Semin Cell Biol 6 5 (1995) 259-268
7. Fair D.S., Marlar R.A., and Levin E.G. Human endothelial cells synthesize protein S. Blood 67 4 (1986) 1168-1171
8. Broze Jr. G.J. Tissue factor pathway inhibitor. Thromb Haemost 74 1 (1990) 90-93
9. Marcum J.A., and Rosenberg R.D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry 23 8 (1984) 1730-1737
10. Tollefsen D.M., and Pestka C.A. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 66 4 (1985) 769-774
11. Majerus P.W., Broze Jr. G.J., Miletich J.P., et al. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman J.G., and Limbird L.E. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition (2006), McGraw-Hill Companies, New York 1341-1359
12. Ross B.P., and Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr Drug Deliv 2 3 (2005) 277-287
13. Salzman E.W., Rosenberg R.D., Smith M.H., et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65 (1980) 64-73
14. Brace L.D., and Fareed J. An objective assessment of the interaction of heparin and its fractions with human platelets. Semin Thromb Hemost 11 (1985) 190-198
15. Warkentin T.E., and Kelton J.G. Heparin-induced thrombocytopenia. Annu Rev Med 30 (1989) 31-44
16. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
17. Warkentin T.E., Sheppard J.I., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
18. Lindhoff-Last E., Gerdsen F., Ackermann H., et al. Determination of heparin-platelet 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol 113 (2001) 886-890
19. Newman P.M., and Chong B.H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96 (2000) 182-187
20. Chong B.H., Murray B., Berndt M.C., et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83 (1994) 1535-1541
21. Warkentin T.E., Hayward C.P.M., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84 (1994) 3691-3699
22. Warkentin T.E., and Sheppard J.I. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. Platelets 10 (1999) 319-326
23. Visentin G.P., Ford S.E., Scott J.P., et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93 (1994) 81-88
24. Greinacher A., Potzsch B., Amiral J., et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71 2 (1994) 247-251
25. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia. 2nd edition (2001), Marcel Dekker Inc, New York 43-86
26. Wallis D.E., Workman D.L., Lewis B.E., et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 106 (1999) 629-635
27. Warkentin T.E., and Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
28. Nand S., Wong W., Yuen B., et al. Heparin induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 56 (1997) 12-16
29. Shields R.C., McBane R.D., Kuiper J.D., et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 76 (2001) 260-266
30. Landesfeld C.S., and Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87 (1989) 144-152
31. Fihn S.D., McDonell M., Martin D., et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 118 (1993) 511-520
32. Palareti G., Ieali N., Coccheri S., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study. Lancet 348 (1996) 423-428
33. van der Meer F.J.M., Rosendaal F.R., Vandenbroucke J.P., et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 153 (1993) 1557-1562
34. Hylek E.M., Heiman H., Skates S.J., et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 259 (1998) 657-662
35. Ansell J., Hirsh J., Dalen J., et al. Managing oral anticoagulant therapy. Chest 119 (2001) 22S-38S
36. Bonow R.O., Carabello B., de Leon Jr. A.C., et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 98 (1998) 1949-1984
37. Horlocker T.T., Benzon H., Brown D.L., et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med 28 (2003) 172-197
38. Tai C.Y., Ierardi R., and Alexander J.B. A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. Ann Vasc Surg 18 (2004) 237-242
39. Gherman R.B., Goodwin T.M., Leung B., et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 94 (1999) 730-734
40. Refuerzo J.S., Hechtman J.L., Redman M.E., et al. Venous thromboembolism during pregnancy. Clinical suspicion warrants evaluation. J Reprod Med 48 (2003) 767-770
41. Hall J.G. Embryopathy associated with oral anticoagulant therapy. Birth Defects 12 (1965) 33-40
42. Sahul W.L., Emery H., and Hall J.G. Chondrodysplasia punctata and maternal warfarin use during pregnancy. Am J Dis Child 129 (1975) 360-362
43. Salazar E., Izaguirre R., Verdejo J., et al. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prosthesis. J Am Coll Cardiol 27 (1996) 1698-1703
44. Iturbe-Alessio I., del Carmen Fonseca M., Mutchinik O., et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 315 (1986) 1390-1393
45. Essex D.W., Wynn S.S., and Jin D.K. Late-onset warfarin-induced skin necrosis: case report and review of the literature. Am J Hematol 57 (1998) 233-237
46. Flood E.P., Redish M.H., Bocik S.J., et al. Thrombophlebitis migrans disseminata: report of a case in which gangrene of a breast occurred. N Y State J Med 43 (1943) 121-124
47. Teepe R.G., Broekmans A.W., Vermeer B.J., et al. Recurrent Coumarin-induced skin necrosis in a patient with an acquired functional protein C deficiency. Arch Dermatol 122 (1986) 1408-1412
48. Grimaudo V., Gueissaz F., Hauert J., et al. Necrosis of skin induced by warfarin in a patient deficient in protein S. BMJ 298 (1989) 233-238
49. Kiehl R., Hellstern P., and Wenzel E. Hereditary ATIII deficiency and atypical localization of warfarin necrosis. [letter]. Thromb Res 45 (1987) 191-193
50. Sallah S., Thomas D.P., and Roberts H.R. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 78 (1997) 785-790
51. Egred M., and Rodrigues F. Purple digit syndrome and warfarin-induced skin necrosis. Eur J Intern Med 16 4 (2005) 294-295
52. Falkon L., Saenz-Campos D., Antonijoan R., et al. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 78 (1995) 77-86
53. Navarro-Quilis A., Castellet E., Rocha E., et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized double blind clinical trial. J Throm Haemost 1 (2002) 425-432
54. Conduah A., and Lieberman J.R. Venous thromboembolic prophylaxis after elective total hip arthroplasty. Clin Orthop 441 (2005) 274-284
55. Bendetowicz A.V., Beguin S., Caplain H., et al. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin-a three way cross over study in human volunteers. Thromb Haemost 71 3 (1994) 305-313
56. Colwell C.W., Spiro T.E., and Trowbridge A. Use of enoxaparin, a low molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement surgery. J Bone Joint Surg [Am] 76 (1994) 3-14
57. Freedman K.B., Brookenthal K.R., Fitzgerald Jr. R.H., et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg [Am] 82 (2000) 929-938
58. Koch A., Ziegler S., and Breitschwerdt H. Low molecular weight heparin and unfractionated heparin in thrombus prophylaxis: a meta-analysis based on original patient data. Thromb Res 102 (2001) 295-309
59. Nurmohamed M.T., Rosendaal F.R., Buller H.R., et al. Low molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 340 (1992) 152-156
60. Young E., Wells P., Holloway S., et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71 (1994) 300-304
61. Leizorovicz A., Haugh M.C., Chapuis F.R., et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 305 (1992) 913-920
62. Cosmi B., and Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 9 (1994) 612-618
63. Egger S.S., Sawatzki M.G., Drewe J., et al. Life threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. Pharmacotherapy 25 6 (2005) 881-885
64. Makris M., Hough R.E., and Kitchen S. Poor reversal of low molecular weight heparin by protamine. Br J Haematol 108 (2000) 884-885
65. Lakhmir S.C., Moore G., and Seneff M.G. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. Obes Surg 14 (2004) 695-698
66. Crowther M.A., Berry L.R., Monagle P.T., et al. Mechanisms responsible for the failure of protamine to inactivate low molecular weight heparin. Br J Haematol 116 (2002) 178-186
67. Racanelli A., Hoppensteadt D.A., and Fareed J. In vitro protamine neutralization profiles of heparins differing in source and molecular weight. Semin Thromb Hemost 15 (1989) 386-389
68. Planes A., Vochelle N., and Fafola M. Venous thromboembolic prophylaxis in orthopedic surgery: knee surgery. Semin Thromb Hemost 25 Suppl 3 (1999) 73-77
69. Hirsh J., Dalen J.E., and Deykin D. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 102 Suppl (1992) S337-S351
70. Hirsh J., and Levine M.N. Low molecular weight heparin. Blood 79 (1992) 1-17
71. Lieberman J.R., and Geerts W.H. Prevention of venous thromboembolism after total hip and knee arthroplasty. J Bone Joint Surg [Am] 76 (1994) 1239-1250
72. Geerts W.H., Heit J.A., Clagett G.P., et al. Prevention of venous thromboembolism. Chest 119 Suppl 1 (2001) 132S-75
73. Stulberg B.N., Insall J.N., Williams G.W., et al. Deep-vein thrombosis following total knee replacement: an analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg [Am] 66 (1984) 194-201
74. Stringer M.D., Steadman C.A., Hedges A.R., et al. Deep vein thrombosis after elective knee surgery: an incidence study in 312 patients. J Bone Joint Surg [Br] 71 (1989) 492-497
75. Mohr D.N., Silverstein M.D., Ilstrup D.M., et al. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 67 (1992) 861-870
76. Khaw F.M., Moran C.G., Pinder I.M., et al. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. J Bone Joint Surg [Br] 75 (1993) 940-941
77. Ansari S., Warwick D., Ackroyd C.E., et al. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. J Arthroplasty 12 (1997) 599-602
78. Clagett G.P., Anderson Jr. F.A., Geerts W.H., et al. Prevention of venous thromboembolism. Chest 114 (1998) 531S-560S
79. Francis C.W., Pellegrini Jr. V.D., Totterman S., et al. Prevention of deep-vein thrombosis after total hip arthroplasty: Comparison of warfarin and dalteparin. J Bone Joint Surg [Am] 79 (1997) 1365-1372
80. Geerts W.H., Pineo G., Heit J., et al. Prevention of venous thromboembolism. Chest 126 (2004) 338S-400S
81. Hamulyak K., Lensing A.W., van der Meer J., et al. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine oral anticoagulant study group. Thromb Haemost 74 (1995) 1428-1431
82. Hull R.D., Raskob G.E., Pineo G., et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329 (1993) 1370-1376
83. Tuman K.J., McCarthy R.J., March R.J., et al. Effects of epidural anesthesia and analgesia on coagulation and outcome after major vascular surgery. Anesth Analg 73 (1991) 696-704
84. Capdevila X., Barthelet Y., Biboulet P., et al. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology 91 (1999) 8-15
85. Bradshaw B.G., Liu S.S., and Thirlby R.C. Standardized perioperative care protocols and reduced length of stay after colon surgery. J Am Coll Surg 186 (1998) 501-506
86. Horlocker T.T., and Wedel D.J. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic. Anesth Analg 86 (1998) 1153-1156
87. Vandermeulen E.P., Van Aken H., and Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 79 (1994) 1165-1177
88. Horlocker T.T. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 101 1 (2001) 141-154
89. Tryba M. Rückmarksnahe regionalanästhesie und niedermolekulare heparine: Pro. Anästh Intensivmed Notfallmed Schmerzther 28 (1993) 179-181
90. Weitz J.I., and Hirsh J. New anticoagulant drugs. Chest 119 (2001) 95S-107S
91. Bauer K.A. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 58 (2001) S14-S17
92. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 12 (2005) 3791-3796
93. Dager W.E., Anderson J., and Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 24 7, pt 2 (2004) 88S-94S
94. Gerotziafas G.T., and Samama M.M. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11 30 (2005) 3855-3876
95. Turpie A.G., Gallus A.S., Hoek J.A., et al., for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 344 (2001) 619-625
96. Lassen M.R., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359 (2002) 1715-1720
97. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359 (2002) 1721-1726
98. Eriksson B.I., Bauer K.A., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 (2001) 1298-1304
99. Bauer K.A., Eriksson B.I., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 (2001) 1305-1310
100. Agnelli G., Bergqvist D., Cohen A.T., et al., on behalf of the PEGASUS Investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 (2005) 1212-1220
101. Buller H.R., Davidson B.L., Decousus H., et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349 (2003) 1695-1702
102. Buller H.R., Davidson B.L., Decousus H., et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140 (2004) 867-873
103. Michelangelo OASIS 5 Steering Committee. Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 150 6 (2005) 1107
104. ARIXTR: A black box warning. Available at: www.fda.gov/medwatch/SAFETY/2004/may_PI/Arixtra_PI.pdf. Accessed September 8, 2006.
105. Tardy-Pancet B., and Tardy B. Heparin-induced thrombocytopenia. Minimizing the risks in the elderly patient. Drugs Aging 16 (2000) 351-364
106. Kumar N., Bentolila A., and Domb A.J. Structure and biological activity of heparinoid. Mini Rev Med Chem 5 5 (2005) 441-447
107. Bode W., and Stubbs M.T. Spatial structure of thrombin as a guide to its multiple sites of interaction. Semin Thromb Hemost 19 (1993) 321-333
108. Stubbs M.T., and Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 69 (1993) 1-58
109. Stubbs M.T., and Bode W. A model for the specificity of fibrinogen cleavage by thrombin. Semin Thromb Hemost 19 (1993) 344-351
110. Chen J.L. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications. Heart Dis 3 (2001) 189-198
111. Swan S.K., and Hursting M.J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic ore renal dysfunction. Pharmacotherapy 20 (2000) 318-329
112. Gold H.K., Torres F.W., Garabedian H.D., et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21 (1993) 1039-1047
113. Jang I.K., Brown D.M., and Giugliano R.P. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction with Novastan and tPA (MINT) study. J Am Coll Cardiol 33 (1999) 1879-1885
114. Vermeer F., Vahanian A., Fels P.W., et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis 10 (2000) 233-240
115. Behar S., Hod H., Kaplinsky E., and for the ARGAMI-2 Study Group. Argatroban versus heparin as adjunctive therapy to thrombolysis for acute myocardial infarction: safety considerations: ARGAMI-2 study. [abstract # 2386]. Circulation 98 (1998) I453-I454
116. Alexander J.H., Greenbaum A.B., Hudson M.P., et al. Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. Am Heart J 135 (1998) 1099-1114
117. Engelmann F., and Stade C. Über die Bedeutung des Blutegelextraktes für die Therapie der Eklampsie. Münch Med Wochenschr 43 (1909) 2203-2207
118. Haas G. Über Versuche der Blutauswaschung am Lebenden mit Hilfe der Dialyse. Arch Pharmacol 116 (1926) 158-172
119. van Wyk V., Neethling W.M., Badenhorst P.N., et al. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons. J Cardiovasc Surg (Torino) 39 5 (1998) 633-639
120. Koster A., Hansen R., Grauhan O., et al. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 14 3 (2000) 249-252
121. Koster A., Loebe M., Hansen R., et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the act II device. J Thorac Cardiovasc Surg 119 6 (2000) 1278-1283
122. Koster A., Loebe M., Mertzlufft F., et al. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg 70 6 (2000) 2160-2161
123. Greinacher A., Völpel H., Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 99 (1999) 73-80
124. Greinacher A., Janssens U., Berg G., et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100 (1999) 587-593
125. Pötzsch B., and Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-induced thrombocytopenia (2000), Marcel Dekker, New York 355-369
126. Fox K.A.A. r-Hirudin in unstable angina pectoris: rationale and preliminary data from the APT pilot study. Eur Heart J 16 (1995) 28-32
127. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation 96 (1997) 769-777
128. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomized trial. Lancet 353 (1999) 429-438
129. Zeymer U., von Essen R., Tebbe U., et al. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study, HIT-I (Hirudin for the Improvement of Thrombolysis). Eur Heart J 16 suppl D (1995) 22-27
130. von Essen R., Zeymer U., Tebbe U., et al. HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte. Coron Artery Dis 9 (1998) 265-272
131. Molhoek G.P., Laarman G.J., Lok D.J., et al. Angiographic dose-finding study with r-hirudin (HBW 023) for the improvement of thrombolytic therapy with streptokinase (HIT-SK): interim results. Eur Heart J 16 Suppl D (1995) 33-37
132. Neuhaus K.L., von Essen R., Tebbe U., et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) Study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 90 (1994) 1638-1642
133. Neuhaus K.L., Molhoek G.P., Zeymer U., et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 34 (1999) 966-973
134. Greinacher A., and Lubenow N. Recombinant hirudin in clinical practice; focus on lepirudin. Circulation 103 (2001) 1479-1484
135. Gladwell T.D. Bivalirudin: a direct thrombin inhibitor. Clin Ther 24 1 (2002) 38-58
136. Campbell K.R., Mahaffey K.W., Lewis B.E., et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invasive Cardiol 12 Suppl F (2000) 14-19
137. Chesebro J.H. Direct thrombin inhibitor therapy in the cardiovascular patient. Am J Health Syst Pharm 60 Suppl 5 (2003) S19-S26
138. Doggrell S. Can bivalirudin and provisional GP IIb/IIIa blockade replace heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?. Expert Opin Pharmacother 4 8 (2003) 1431-1433
139. Merry A.F., Raudkivi P.J., Middleton N.G., et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 77 3 (2004) 925-931
140. Eriksson U.G., Bredberg U., Hoffman K.J., et al. Absorption, distribution, metabolism and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs and humans. Drug Metab Dispos 31 (2003) 294-305
141. Johansson L.C., Frison L., Logren U., et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 42 (2003) 381-392
142. Samama M.M., Gerotziafas G.T., Elalamy I., et al. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 32 (2002) 218-224
143. Carlsson S.C., Mattsson C., Eriksson U.G., et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 115 (2005) 9-18
144. Mattsson C., Menschiek-Lundin A., Wahlander K., et al. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 86 (2001) 611-615
145. Johansson L.C., Andersson M., Fager G., et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 42 (2003) 475-484
146. Sarich T.C., Teng R., Peters G.R., et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 42 (2003) 485-492
147. Eriksson U.G., Johansson S., Attman P.O., et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 42 (2003) 743-753
148. Gruber A., Carlsson S., Kotze H., et al. Activated factor VII is hemostatic without promoting thrombus propagation. [abstract 2998]. Blood 102 11 (2003) 809
149. Reiffel J.A. The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. Rev Cardiovasc Med 5 Suppl 5 (2004) S12-S21
150. Francis C.W., Ginsberg J.S., Berkowitz S.D., et al., the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. [abstract 7]. Blood 102 (2003)
151. Eriksson H., Wåhlander K., Gustafsson D., et al. THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 1 (2003) 41-47
152. Schulman S. The role of ximelagatran in the treatment of venous thromboembolism. Pathophysiol Haemost Thromb 34 Suppl 1 (2005) 18-24
153. Schulman S., Wahlander K., Lundstrom T., et al., for the THRIVE III investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 349 (2003) 1713-1721
154. Eriksson B.I., Bergqvist D., Kalebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial. Lancet 360 (2002) 1441-1447
155. Eriksson B.I., Agnelli G., Cohen A.T., et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. The EXPRESS study. J Thromb Haemost 1 (2003) 2490-2496
156. Francis C.W., Davidson B.L., Berkowitz S.D., et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 137 (2002) 648-655
157. Francis C.W., Berkowitz S.D., Comp P.C., et al., for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349 (2003) 1703-1712
158. Colwell C.W., Berkowitz S.D., Comp P.C., et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. [abstract 39]. Blood 102 11 (2003)
159. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
160. Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular artial fibrillation. JAMA 293 6 (2005) 690-698
161. Department of health and human services food and drug administration center for drug evaluation and research cardiovascular and renal drugs advisory committee. September 10, 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4069T1.pdf. Accessed January 30, 2006.
162. Adelman B., Michelson A.D., Handin R.I., et al. Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood 66 2 (1985) 423-427
163. Michelson A.D., Adelman B., Barnard M.R., et al. Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest 81 6 (1988) 1734-1740
164. Michelson A.D., and Furman M.I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 6 5 (1999) 342-348
165. Mustard J.F., and Packham M.A. Factors influencing platelet function: adhesion, release and aggregation. Pharmacol Rev 22 (1970) 97-187
166. Weiss H.J., Aledort L.M., and Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 47 9 (1968) 2169-2180
167. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325 (1991) 1261-1266
168. Ishikawa K., Kanamasa K., Hama J., et al. Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. Jpn Circ J 61 1 (1997) 38-45
169. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
170. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
171. Michelson A.D., Cattaneo M., Eikelboom J.W., et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 6 (2005) 1309-1311
172. O'Connor F.F., Shields D.C., Fitzgerald A., et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 98 (2001) 3256-3260
173. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 6 (2004) 1122-1126
174. Bybee K.A., Powell B.D., Valeti U., et al. Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting. Circulation 112 Suppl 9 (2005) I286-I292
175. Cobb C.J., Chakrabarti S., Chadha V., et al. The effect of aspirin and warfarin therapy in trabeculectomy. Eye (2006) [Epub ahead of print]
176. Madan G.A., Madan S.G., Madan G., et al. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 63 9 (2005) 1262-1265
177. Herbert J.M., Dol F., Bernat A., et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 80 (1998) 512-518
178. Hass W.K., Easton J.D., Adams H.P.J., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321 (1989) 801-807
179. Bertrand M.E., Rupprecht H.J., Urban P., et al., for the investigators of the double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 6 (2000) 624-629
180. Manor S.M., Guillory G.S., and Jain S.P.P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy 24 5 (2004) 664-667
181. Andersohn F., Hagmann F.G., and Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 90 (2004) e57-e59
182. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 5 (2000) 891-896
183. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events. Lancet 348 9038 (1996) 1329-1339
184. Leon M.B., Baim D.S., Popma J.J., et al., for the Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. N Engl J Med 339 (1998) 1665-1671
185. McFadden E.P., Stabile E., Regar E., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 9444 (2004) 1519-1521
186. Hongo R.H., Ley J., Dick S.E., et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 40 2 (2002) 231-237
187. Sreeram G.M., Sharma A.D., and Slaughter T.F. Platelet glycoprotein IIb/IIIa antagonists: perioperative implications. J Cardiothorac Vasc Anesth 15 (2001) 237-240
188. Tcheng J.E. Clinical challenges of platelet glycoprotein IIbIIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia and retreatment. Am Heart J 139 (2000) S38-S45
189. Popma J.J., Weitz J., Bittl J.A., et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 114 5 Suppl (1998) 728S-741S
190. Patrono C., Coller B., Dalen J.E., et al. Platelet-active drugs: the relationship among dose, effectiveness, and side effects. Chest 119 (2001) 39S-63S
191. Karvouni E., Katritsis D.G., and Ioannidis J.P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41 1 (2003) 26-32
192. Tcheng J.E., O'Shea J.C., Cohen E.A., et al., for the ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo controlled trial. Lancet 356 9247 (2000) 2037-2044
193. Bhatt D.L., Marso S.P., Lincoff A.M., et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 35 4 (2000) 922-928
194. Chen L., Bracey A.W., Radovancevic R., et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 128 3 (2004) 425-431
195. Nuttall G.A., Oliver W.C., Santrach P.J., et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 94 5 (2001) 773-781
196. Shore-Lesserson L., Manspeizer H.E., DePerio M., et al. Thromboelastography guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 88 2 (1999) 312-319
197. Spiess B.D., Gillies B.S., Chandler W., et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 9 2 (1995) 168-173
198. Chesebro J.H. Direct thrombin inhibitor therapy in the cardiovascular patient. Am J Health Syst Pharm 60 Suppl 5 (2003) S19-S26
199. Babka R., Colby C., El-Etr A., et al. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 73 5 (1977) 780-782
200. Bull M.H., Huse W.M., and Bull B.S. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 43 3 (1975) 346-353
201. Despotis G.J., Summerfield A.L., Joist J.H., et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 108 6 (1994) 1076-1082
202. Esposito R.A., Culliford A.T., Colvin S.B., et al. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 85 2 (1983) 174-185
203. Gravlee G.P., Haddon W.S., Rothberger H.K., et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 99 3 (1990) 518-527
204. Cherng Y.G., Chao A., Shih R.L., et al. Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin 36 4 (1998) 179-186
205. Craft R.M., Chavez J.J., Bresee S.J., et al. A novel modification of the Thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 143 5 (2004) 301-309
206. Essell J.H., Martin T.J., Salinas J., et al. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vase Anesth 7 (1993) 410-415
207. Grant H.W., and Hadley G.P. Prediction of neonatal sepsis by thromboelastography. Pediatr Surg Int 12 4 (1997) 289-292
208. Khurana S., Mattson J.C., Westley S., et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 130 4 (1997) 401-411
209. Mortier E., Ongenae M., De Baerdemaeker L., et al. In vitro evaluation of the effect of profound haemodilution with hydroxyethyl starch 6%, modified fluid gelatin 4% and dextran 40 10% on coagulation profile measured by thromboelastography. Anaesthesia 52 11 (1997) 1061-1064
210. Trentalange M.J., and Walts L.F. A comparison of thromboelastogram and template bleeding time in the evaluation of platelet function after aspirin ingestion. J Clin Anesth 3 (1991) 377-381
211. Khurana S., Mattson J.C., Westley S., et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 130 4 (1997) 401-411
212. Coller B.S., Lang D., and Scudder L.E. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 95 4 (1997) 860-867
213. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 21 (2001) 2572-2578
214. Carville D.G., Schleckser P.A., Guyer K.E., et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 30 4 (1998) 171-177
215. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 1 (2003) 32-37
216. Weiss M., Stone M., Mitchell-Bligen M., et al. Point-of-care devices detect the clopidogrel-induced inhibition of platelet aggregation as well as aggregometry. Anesth Analg 100 (2005) SCA55
217. Bock M., De Haan J., Beck K.H., et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 106 4 (1999) 898-904